Hospital Excellence Profile
Taipei Veterans
General Hospital
General Hospital
28 active SNQ certifications · Taipei · Medical Center · Est. 1959
SNQ · Valid 2026
Medical Center
Osteosarcoma
95%
Limb salvage rate
Head & Neck Cancer
NCCN
Guideline cited
Fabry Disease
Asia #1
Largest cohort
Brain Tumour (BNCT)
67%
Tumour response rate
Renal Cell Carcinoma
98.6%
5-yr overall survival
PROMs
Stroke
Heart Failure
Heart Failure
Excellence by Specialty
▾All
Oncology & Haematology
Neurology & Neurosurgery
Cardiovascular Medicine
Nephrology & Renal Care
Urology & Andrology
Psychiatry & Neuroscience
Rare & Infectious Disease
Orthopaedic Surgery
Obstetrics & Gynaecology
Otolaryngology (ENT)
Oral Medicine
| Disease / Procedure | Key outcome | vs. Global benchmark | Collaboration |
|---|---|---|---|
Cardiovascular Medicine Atrial fibrillation — catheter ablation |
80% 5-yr AF-free rate |
vs. 1–2% complication avg · 300+ cases/yr |
|
Cardiology / Cardiac Surgery Cardiovascular tissue bank |
— Vascular & heart valve allografts |
National tissue bank |
|
GI Surgery Gastric cancer — personalized resection |
98% R0 resection rate · 76% 5-yr survival |
vs. 90–93% global avg |
|
GI Surgery Colorectal cancer — comprehensive integration |
82% 5-yr overall survival (stage I–III) |
anastomotic leak <3% vs. 5–8% global avg |
|
Interventional Radiology Liver cancer — Y-90 radioembolization |
91% Disease control rate at 3 months |
radiation hepatitis <5% vs. 8–15% global avg |
|
Gastroenterology Liver cancer — AI recurrence prediction |
91% AI prediction accuracy |
international leading model |
|
GI Surgery Pancreatic cancer — surgery & treatment |
36.9% 5-yr survival · robotic surgery |
vs. 12% global avg |
|
GI Surgery / Transplant Pancreas transplantation |
92% 1-yr graft survival |
insulin independence 90% vs. 85% US avg |
|
Neuro-Oncology Brain tumour — BNCT |
67% Tumour response rate at 1 month |
322 cases · World #1 volume |
|
ENT / Head & Neck Surgery Head & neck cancer — multidisciplinary care |
75% 5-yr laryngeal preservation |
92% swallowing retention vs. 60–65% global avg |
|
Thoracic Medicine Lung tumour — multidisciplinary care |
85% Localisation accuracy · 5-yr survival |
SNQ 2024 · SNQ Bronze 2022 |
|
Orthopedic Oncology Osteosarcoma — biological reconstruction |
95% Limb salvage rate |
5-yr DFS 78% vs. 65–70% global avg |
|
Neurology & Neurosurgery Spontaneous intracranial hypotension |
92% Targeted patch success rate |
vs. 70–80% global avg · world #1 series |
|
Neurology & Neurosurgery Epilepsy surgery |
75% Post-surgery seizure-free rate |
vs. 60–65% global avg |
|
Neurology & Neurosurgery Chronic migraine & headache |
70% Chronic migraine improvement rate |
National #1 headache centre |
|
Neurosurgery Cerebral AVM — Gamma Knife radiosurgery |
95% AVM obliteration rate |
vs. 85–90% global avg |
|
Urology & Andrology Renal cell carcinoma — robotic partial nephrectomy |
98.6% 5-yr overall survival |
negative margins 100% · complication 4.4% vs. 8% avg |
|
Urology / Andrology Azoospermia — precision reproductive medicine |
65% Sperm retrieval rate (micro-TESE) |
clinical pregnancy rate 42% vs. 30–35% global avg |
|
Nephrology & Renal Care Renal anaemia — treatment guidelines |
92% Target Hb achievement rate |
KDIGO & ESA cited · Taiwan-pioneered protocol |
|
Nephrology & Renal Care Dialysis vascular access — far-infrared therapy |
78% Access patency at 2 years |
vs. 55–60% global avg · access failure ↓40% |
|
Nephrology & Renal Care Peritoneal dialysis — comprehensive innovation |
92% Technique survival at 2 years |
peritonitis 0.3/pt-yr vs. 0.5 ISPD benchmark |
|
Rare Disease / Paediatrics Fabry disease — research & treatment centre |
90% Renal function preservation at 10yr |
vs. 60% without ERT · Asia #1 cohort |
|
Infectious Disease Klebsiella liver abscess — comprehensive care |
96% Clinical cure rate |
0 metastatic spread · national reference |
|
Psychiatry & Neuroscience Precision psychiatry — AI diagnosis & rTMS |
91.7% AI diagnostic accuracy |
87 rTMS patients · Edison Gold 2025 |
|
Orthopedics / Spine Scoliosis correction surgery |
73°→18° Avg Cobb angle correction |
0% neurological deficit |
|
Obstetrics & Gynaecology Endometriosis — fertility preservation therapy |
85% Recurrence-free at 2yr |
world-first post-surgery protocol |
|
Otolaryngology (ENT) Cholesteatoma — surgery & hearing rehabilitation |
96% Disease-free at 5yr |
85% hearing improvement vs. 80–85% global avg |
|
Oral Medicine Orofacial pain & cranio-mandibular disorders |
88% Pain resolution rate at 6 months |
national #1 multidisciplinary pain team |
Hospital Quality Indicators
5
Safety of Care
Infection · Complications
5
Timely & Effective Care
Sepsis · ED · VTE
5
Mortality Rates
30-day · Risk-adjusted
5
Readmission Rates
30-day · All-cause
5
Medication Safety
CPOE · BCMA · Reconciliation
5
Clinical Staffing
Nurse · ICU · Physician
5
Patient Experience
Satisfaction · Safety · Environment
27
SNQ Certifications
27 certified programmes
Surgical Site Infection Rate
Post-operative SSI
CLABSI Rate
Central line bloodstream infections
CAUTI Rate
Catheter-associated UTI
Hand Hygiene Compliance
Healthcare worker adherence
Serious Complications Index
Risk-adjusted surgical complications
Sepsis Protocol Compliance
Severe sepsis care
ED Median Wait Time
Emergency dept wait
VTE Prophylaxis Rate
Thromboembolism prevention
Influenza Vaccination Rate
Healthcare workers
Antithrombotic Therapy
Stroke patients
In-Hospital Mortality Rate
Risk-adjusted all-cause
Heart Failure 30-Day
30-day mortality
Stroke 30-Day
30-day mortality
Pneumonia 30-Day
30-day mortality
Post-Surgical Mortality
Treatable complications
Hospital-Wide 30-Day Readmission
All-cause unplanned
Heart Failure Readmission
30-day readmission
Hip / Knee Surgery Readmission
Post-surgery
Post-Chemotherapy ED Visits
Outpatient chemo
Post-Surgery Unplanned Visits
Outpatient surgery
CPOE Implementation
Computerised order entry
Barcode Medication Admin
BCMA compliance
Medication Reconciliation
Admission/discharge review
Adverse Drug Event Rate
Per 1,000 patients
Chemotherapy Error Rate
Prescription & admin
Nurse-to-Patient (General)
RN hours per patient day
Nurse-to-Patient (ICU)
ICU RN ratio
ICU Physician Coverage
Intensivist-led model
Specialist Physician Density
Per 100 inpatient beds
Nursing Turnover Rate
Workforce stability
Overall Satisfaction
Hospital stay rating
Patient Safety Experience
Safety perception
Service & Process
Admission/discharge/wait
Environment & Facilities
Cleanliness & comfort
Recommendation Rate
Willingness to recommend
Brain Tumour
Neuro-Oncology
Pancreatic Cancer
GI Surgery
Osteosarcoma
Orthopedic Oncology
Head & Neck Cancer
ENT
Liver Cancer — Y-90
Interventional Radiology
Colorectal Cancer
GI Surgery
Gastric Cancer
GI Surgery
Lung Tumour
Thoracic Medicine
Pancreas Transplantation
Transplant Surgery
Atrial Fibrillation Ablation
Cardiology
Cardiovascular Tissue Bank
Cardiac Surgery
SIH
Neurology
Epilepsy Surgery
Neurology
Chronic Migraine
Neurology
Cerebral AVM
Neurosurgery
Renal Cell Carcinoma
Urology
Azoospermia
Urology / Andrology
Renal Anaemia
Nephrology
Dialysis FIR Therapy
Nephrology
Peritoneal Dialysis
Nephrology
Fabry Disease
Rare Disease
Klebsiella Liver Abscess
Infectious Disease
Precision Psychiatry
Psychiatry
Scoliosis
Orthopedics
Endometriosis
Gynaecology
Cholesteatoma
ENT
Orofacial Pain
Oral Medicine
Global Collaboration
🇺🇸
Mayo Clinic
Rochester / Jacksonville, USA
R&D Partnership
Joint Heavy-Ion Radiation Research Laboratory
In November 2024, VGHTP and Mayo Clinic Florida established a Joint Heavy-Ion Radiation Research Laboratory on-site — where Mayo researchers collaborate on radiobiology, dosing protocols, and patient selection. Co-submissions to Taiwan NSTC and the US NIH are in progress. Read more ▾ Mayo brings deep translational infrastructure; VGHTP contributes the largest non-Japanese carbon-ion clinical dataset. Mayo's Florida campus is building the first carbon-ion centre in the US — making this a foundational research partnership for the field's next chapter.
350+
Patients treated with heavy-ion therapy
2025
Joint lab operational since Jan
NIH
Joint grant applications in progress
"Together we will further advance the quality and quantity of cancer radiation therapy in both Taiwan and the United States." — President Chen Wei-Ming, VGHTP
🇻🇳
Cho Ray Hospital
Ho Chi Minh City, Vietnam
Physician Training
Six-Year Clinical Training & Academic Exchange Partnership
Since 2019, VGHTP and Cho Ray Hospital have built one of Taiwan's most active bilateral medical partnerships. Cho Ray physicians complete hands-on training at VGHTP; VGHTP faculty co-hosted the 2024 Taiwan–Vietnam Medical Forum in Hanoi. Read more ▾ In July 2025, a joint symposium in Ho Chi Minh City drew 400+ specialists and 35 speakers — covering heavy-ion therapy, immunotherapy, liver transplantation, and AI applications — alongside 46 industry partners from both nations.
400+
Experts at 2025 forum
6 yrs
Continuous bilateral partnership
46
Industry partners involved
"This partnership is a bridge to continuously update the most advanced medical knowledge and fulfil our shared mission of patient care." — Dr. Lam Viet Trung, Vice President, Cho Ray Hospital
🇺🇸
NYU Langone Health
New York, USA
International Patients
Pancreatic Cancer Treatment & Research Partnership
VGHTP's pancreatic cancer heavy-ion programme achieved 82.3% first-year survival — results that directly attracted NYU Langone's oncology leadership. In August 2025, President Chen and incoming NYU Langone CEO Prof. Kimmelman signed a research contract making pancreatic cancer the priority focus. Read more ▾ Both the outgoing CEO Robert Grossman and incoming CEO Kimmelman attended the signing — a rare gesture reflecting the depth of NYU Langone's commitment. The visit also included meetings with SBRT programme director Dr. Anand Mahadevan and a tour of advanced radiotherapy facilities including MR-LINAC.
550+
Heavy-ion patients treated since 2023
82.3%
Pancreatic cancer 1-yr survival rate
36.9%
5-yr survival · vs. 5–10% global average
"Pancreatic cancer as the priority focus — advancing heavy-ion treatment, patient referrals, and shared research outcomes." — VGHTP × NYU Langone Health, Research Contract, August 2025